

## Montanide™ ISA 78 VG, a new powerful adjuvant for poultry vaccines

To support the growth of poultry farming and meet the need of more efficient and safer poultry vaccines, Seppic enlarges its range of oily adjuvants with **Montanide™ ISA 78 VG**. Montanide™ ISA 78 VG is an innovative alternative to Montanide™ ISA 71 VG and Montanide™ ISA 71R VG. Designed for **water-in-oil emulsions**, this novel adjuvant is particularly **stable and powerful**.

Montanide™ ISA 78 VG is an oily adjuvant boosted by an **immunostimulating compound**. Its composition, based on enriched oil, induces an antigen-specific cell-mediated immune response that is stronger than for reference adjuvants, thus providing an enhanced **protection against viral diseases**. Its innovative immunostimulant composition triggers a **fast** onset of immunity to protect very young birds.

Seppic continues to innovate and to offer more and more **expertise** to its customers with effective, safe and ready-to-use adjuvants. Montanide™ ISA 78 VG provides a powerful tool to control detrimental viral and bacterial disease in poultry farming and to contribute to public health with the control of zoonotic diseases.

François Bertrand, Animal Health and Human Biologicals activity manager, stated: *“Innovation is at the heart of our development. We make continuous progress to find new solutions for more efficient, safer and more stable poultry vaccines. The properties of this new adjuvant will make the difference for vaccine producers worldwide and contribute to a healthier future for all.”*

### **Seppic in brief**

A company of Air Liquide Healthcare, Seppic designs and markets a wide range of **specialty ingredients for health and beauty**. Present in **100 countries** through its subsidiaries and its network of distributors, Seppic employs **770 people** worldwide, including **100 employees dedicated to innovation**. [www.seppic.com](http://www.seppic.com)

### **Air Liquide Healthcare**

Supplies **medical gases, home healthcare services, hygiene products, medical equipment and specialty ingredients**.

In 2019, it served over **15,000 hospitals and clinics** and more than **1.7 million patients** at home throughout the world. The Group's Healthcare business reached **€3,693 million in revenues in 2019**, with the support of its **16,500 employees**.

### **MEDIA CONTACTS**

#### **Seppic Communications**

Alexandra Gilbert  
+33 (0)1 42 91 41 18

#### **FP2COM for Seppic**

Florence Portejoie  
+33 (0)6 07 76 82 83

A world leader in gases, technologies and services for Industry and Health, Air Liquide is present in 80 countries with approximately 67,000 employees and serves more than 3.7 million customers and patients. Oxygen, nitrogen and hydrogen are essential small molecules for life, matter and energy. They embody Air Liquide's scientific territory and have been at the core of the company's activities since its creation in 1902.

Air Liquide's ambition is to be a leader in its industry, deliver long term performance and contribute to sustainability. The company's customer-centric transformation strategy aims at profitable, regular and responsible growth over the long term. It relies on operational excellence, selective investments, open innovation and a network organization implemented by the Group worldwide. Through the commitment and inventiveness of its people, Air Liquide leverages energy and environment transition, changes in healthcare and digitization, and delivers greater value to all its stakeholders.

Air Liquide's revenue amounted to 22 billion euros in 2019 and its solutions that protect life and the environment represented more than 40% of sales. Air Liquide is listed on the Euronext Paris stock exchange (compartment A) and belongs to the CAC 40, EURO STOXX 50 and FTSE4Good indexes.

[www.seppic.com](http://www.seppic.com)

Follow us [Twitter](#) and [LinkedIn](#)